Hospital for Special Surgery to use Orgenesis' Tissue Genesis Icellator in rotator cuff repair study

Carly Behm -   Print  |

Orgenesis is enrolling patients for a clinical trial for its Tissue Genesis Icellator at New York City-based Hospital for Special Surgery, the company announced June 10.

The phase 2, randomized placebo-controlled trial will evaluate safety and efficacy of autologous stromal and vascular fraction cells that are injected after rotator cuff repair. Fifty-six patients are expected to be enrolled.

The Tissue Genesis Icellator was acquired by Orgenesis in 2020. It's an investigational device in the U.S. and is a system for recovering autologous stromal and vascular fraction cells from fat tissue.

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers